Patents by Inventor Thomas Renné

Thomas Renné has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Binding molecule activating FXII
    Patent number: 11846641
    Abstract: The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: December 19, 2023
    Assignee: Universitaetsklinikum Hamburg-Eppendorf
    Inventor: Thomas Renné
  • Binding Molecule Activating FXII
    Publication number: 20200182890
    Abstract: The present invention relates to a binding molecule, in particular an antibody or binding fragment thereof, capable of activating FXII, which binds to the proline rich domain of FXII. In particular, the invention is directed to FXII activating antibodies or binding fragments thereof which binds to the proline rich domain of FXII. The invention also encompasses the use of the binding molecule directed to the proline rich domain of FXII as blood coagulation activator, e.g. in diagnostic blood coagulation tests. Corresponding methods and blood coagulation test are also encompassed.
    Type: Application
    Filed: June 28, 2018
    Publication date: June 11, 2020
    Inventor: Thomas Renné
  • Treatment of diseases linked to pathological kinin formation
    Patent number: 8715672
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: May 6, 2014
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renne
  • TREATMENT OF DISEASES LINKED TO PATHOLOGICAL KININ FORMATION
    Publication number: 20130164301
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 27, 2013
    Applicant: CSL Behring GmbH
    Inventors: Bernhard NIESWANDT, Thomas RENNÉ
  • PREVENTION OF THROMBUS FORMATION AND/OR STABILIZATION
    Publication number: 20120148688
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Application
    Filed: December 29, 2011
    Publication date: June 14, 2012
    Inventors: Bernhard Nieswandt, Thomas Renné
  • Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
    Patent number: 8119137
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: February 21, 2012
    Assignee: CSL Behring GmbH
    Inventors: Bernhard Nieswandt, Thomas Renné
  • Prevention of Thrombus Formation and/or Stabilization
    Publication number: 20080254039
    Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and preventing the formation and/or the stabilization of three-dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.
    Type: Application
    Filed: December 20, 2005
    Publication date: October 16, 2008
    Inventors: Bernhard Nieswandt, Thomas Renne